Segui
giulio cerea
giulio cerea
Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Email verificata su ospedaleniguarda.it
Titolo
Citata da
Citata da
Anno
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
7652017
Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal …
G Cerea, M Vaghi, A Ardizzoia, S Villa, R Bucovec, S Mengo, G Gardani, ...
Anticancer research 23 (2C), 1951-1954, 2003
1362003
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer …
A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019
1312019
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ...
European Journal of Cancer 130, 155-167, 2020
1092020
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ...
British journal of cancer 113 (12), 1730-1734, 2015
802015
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
C Gridelli, F Morgillo, A Favaretto, F De Marinis, A Chella, G Cerea, ...
Annals of oncology 22 (7), 1528-1534, 2011
642011
Activity of EGFR TKIs in Caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations
A Passaro, A Prelaj, L Bonanno, M Tiseo, A Tuzi, C Proto, R Chiari, ...
Clinical lung cancer 20 (2), e186-e194, 2019
522019
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
FG De Braud, L Pilla, M Niger, S Damian, B Bardazza, A Martinetti, ...
Journal of Clinical Oncology 32 (15_suppl), 2502-2502, 2014
502014
Alka-372-001: First-in-human, phase I study of entrectinib–an oral pan-trk, ROS1, and ALK inhibitor–in patients with advanced solid tumors with relevant molecular alterations.
FG De Braud, M Niger, S Damian, B Bardazza, A Martinetti, G Pelosi, ...
Journal of Clinical Oncology 33 (15_suppl), 2517-2517, 2015
472015
Treatment of metastatic neuroendocrine carcinomas based on WHO classification
S Artale, L Giannetta, G Cerea, D Maggioni, P Pedrazzoli, I Schiavetto, ...
Anticancer research 25 (6C), 4463-4469, 2005
452005
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
F Cappuzzo, A Morabito, N Normanno, P Bidoli, A Del Conte, L Giannetta, ...
Lung Cancer 99, 31-37, 2016
352016
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
C Gridelli, S Novello, N Zilembo, A Luciani, AG Favaretto, F De Marinis, ...
Journal of Thoracic Oncology 9 (5), 733-737, 2014
352014
Eosinophilic myocarditis: a paraneoplastic event
E Ammirati, M Stucchi, M Brambatti, F Spanò, E Bonacina, F Recalcati, ...
The Lancet 385 (9986), 2546, 2015
322015
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy
A Sartore-Bianchi, EG Pizzutilo, G Marrapese, F Tosi, G Cerea, S Siena
Expert Review of Anticancer Therapy 20 (5), 333-341, 2020
312020
Efficacy and safety of anti-PD-1 immunotherapy in patients aged≥ 75 years with non–small-cell lung cancer (NSCLC): an Italian, multicenter, retrospective study
A Luciani, A Marra, L Toschi, D Cortinovis, S Fava, V Filipazzi, A Tuzi, ...
Clinical Lung Cancer 21 (6), e567-e571, 2020
262020
Rationale and clinical results of multi-target treatments in oncology
A Sartore-Bianchi, R Ricotta, G Cerea, MR Maugeri, S Siena
The International journal of biological markers 22 (1_suppl4), 77-87, 2007
252007
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
AM Schram, AE Drilon, T Macarulla, EM O'Reilly, J Rodon, BM Wolpin, ...
J Clin Oncol 38 (15 suppl), 2020
222020
Cetuximab for treatment of metastatic colorectal cancer
G Cerea, R Ricotta, I Schiavetto, MR Maugeri, A Sartore-Bianchi, ...
Annals of Oncology 17, vii66-vii67, 2006
222006
Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs circulating tumor DNA
G Patelli, C Vaghi, F Tosi, G Mauri, A Amatu, D Massihnia, S Ghezzi, ...
Targeted Oncology 16, 309-324, 2021
202021
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer
SR Volovat, TE Ciuleanu, P Koralewski, JEG Olson, A Croitoru, K Koynov, ...
Oncotarget 11 (33), 3105, 2020
162020
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20